1. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer 
Mark A. Socinski, MD, Coleman Obasaju, MD, PhD, David Gandara, MD, Fred R. Hirsch, MD, Philip Bonomi, MD, Paul A. Bunn, MD, Edward S. Kim, MD, Corey J. Langer, MD, Ronald B. Natale, MD, Silvia Novello, MD, PhD, Luis Paz-Ares, MD, Maurice Pérol, MD, Martin Reck, MD, Suresh S. Ramalingam, MD, Craig H. Reynolds, MD, David R. Spigel, MD, Heather Wakelee, MD, Nick Thatcher, MB, BChir 
Journal of Thoracic Oncology 
Volume 13, Issue 2, Pages (February 2018)
DOI: /j.jtho
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Proposed treatment algorithm for advanced squamous-cell lung cancer (SqCLC) for patients with performance status 0 to 1. aPemetrexed-based platinum combinations are not indicated for SqCLC. bIn Europe, patients with EGFR-expressing tumors only. cIf patient has not previously received anti-PD-1 or -PD-L1 treatment, including first-line pembrolizumab. dPD-L1 ≥1%. eErlotinib is indicated in unselected patients in Europe, but only indicated for patients with EGFR-mutation-positive tumors in the United States in this setting. Selected patients with SqCLC should be tested for EGFR mutations, and if positive, genotypically driven therapy should be pursued, ahead of chemotherapy or immunotherapy. BSC, best supportive care; EGFR, epidermal growth factor receptor; PD-1, programmed death receptor 1; PD-L1, programmed death ligand 1; PS, performance status.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Proposed treatment algorithm for advanced squamous-cell lung cancer (SqCLC) for patients with performance status 2. aTreatment choice will be dependent on additional factors such as presence of co-morbidities, advanced age, toxicity profile, and patient preference. bPemetrexed-based platinum combinations are not indicated for SqCLC. cIn Europe, patients with EGFR-expressing tumors only. dErlotinib is indicated in unselected patients in Europe, but only indicated for patients with EGFR-mutation-positive tumors in the United States in this setting. Selected patients with SqCLC should be tested for EGFR mutations, and if positive, genotypically driven therapy should be pursued, ahead of chemotherapy or immunotherapy. BSC, best supportive care; EGFR, epidermal growth factor receptor; PD-L1, programmed death ligand 1; PS, performance status.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions